Cefiderocol

Cephalosporin Antibacterial — ANTIINFECTIVES FOR SYSTEMIC USE

Key facts

Cefiderocol is an onp drug in the Cephalosporin Antibacterial class catalogued in DrugCentral. It was first approved by the FDA in 2019. DrugCentral lists 12 molecular targets, including ftsI, ftsI and ftsI. Recorded indications include Bacterial urinary infection, Escherichia coli urinary tract infection, Gram-Negative Bacterial Infections and Proteus urinary tract infection.

• Approval status: onp (first approved 2019 by the FDA).
• Drug class: Cephalosporin Antibacterial.
• Molecular targets: ftsI, ftsI, ftsI and mrdA (12 listed in DrugCentral).
• Indications: Bacterial urinary infection, Escherichia coli urinary tract infection, Gram-Negative Bacterial Infections, Proteus urinary tract infection and Pseudomonas urinary tract infection and others.
• ATC code: J01DI04 (Other cephalosporins and penems).
• Molecular formula: C30H34ClN7O10S2; molecular weight 752.23 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (8)

• Bacterial urinary infection
• Escherichia coli urinary tract infection
• Gram-Negative Bacterial Infections
• Proteus urinary tract infection
• Pseudomonas urinary tract infection
• Pyelonephritis
• Urinary tract infection caused by Klebsiella
• Urinary tract infectious disease

Mechanism & targets

• Established pharmacologic class: Cephalosporin Antibacterial

Molecular targets (12)

Target	Gene	Action	Activity
Peptidoglycan synthase FtsI	ftsI	inhibitor	IC50 7.40
Peptidoglycan D,D-transpeptidase FtsI	ftsI	inhibitor	IC50 7.22
Peptidoglycan D,D-transpeptidase FtsI	ftsI	inhibitor	IC50 7.21
Peptidoglycan D,D-transpeptidase MrdA	mrdA	inhibitor	IC50 7.20
Peptidoglycan D,D-transpeptidase FtsI	ftsI	inhibitor	IC50 6.17
Penicillin-binding protein 1A	mrcA	inhibitor	IC50 6.07
Penicillin-binding protein 1A	ponA	inhibitor	IC50 5.98
Peptidoglycan D,D-transpeptidase MrdA	mrdA	inhibitor	IC50 5.66
Penicillin-binding protein 1A	mrcA	inhibitor	IC50 5.48
Penicillin-binding protein 1B	mrcB	inhibitor	IC50 5.47
Penicillin-binding protein 1B	mrcB	inhibitor	IC50 5.46
Penicillin-binding protein 4	pbpD_1	inhibitor	IC50 5.44

Regulatory approvals (2)

Date	Agency	Marketed as	Applicant	Orphan
2020-04-23	EMA	—	Shionogi B.V.
2019-11-14	FDA	—	SHIONOGI INC

ATC classification

ATC code	Therapeutic hierarchy
J01DI04	ANTIINFECTIVES FOR SYSTEMIC USE › ANTIBACTERIALS FOR SYSTEMIC USE › OTHER BETA-LACTAM ANTIBACTERIALS › Other cephalosporins and penems

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Death	305.7
Drug resistance	248.8
Pathogen resistance	179.8
Treatment failure	140.2

Chemical structure

• Molecular formula: C₃₀H₃₄ClN₇O₁₀S₂
• Molecular weight: 752.23 g/mol
• CAS number: —
• InChIKey: DBPPRLRVDVJOCL-FQRUVTKNSA-N
• PubChem CID: 77843966

CC(C)(O\N=C(/C(=O)N[C@H]1[C@H]2SCC(C[N+]3(CCNC(=O)C4=CC=C(O)C(O)=C4Cl)CCCC3)=C(N2C1=O)C([O-])=O)C1=CSC(N)=N1)C(O)=O

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Cefiderocol used for?

DrugCentral lists the following indications for Cefiderocol: Bacterial urinary infection, Escherichia coli urinary tract infection, Gram-Negative Bacterial Infections, Proteus urinary tract infection, Pseudomonas urinary tract infection, Pyelonephritis, Urinary tract infection caused by Klebsiella and Urinary tract infectious disease.

How does Cefiderocol work?

Its molecular targets in DrugCentral include ftsI (inhibitor), ftsI (inhibitor), ftsI (inhibitor) and mrdA (inhibitor).

When was Cefiderocol first approved?

Cefiderocol was first approved by the FDA in 2019.

What drug class does Cefiderocol belong to?

Cefiderocol is in the Cephalosporin Antibacterial class.

What is the chemical formula of Cefiderocol?

Cefiderocol has the molecular formula C30H34ClN7O10S2 and a molecular weight of 752.23 g/mol.

Sources

• DrugCentral drug card 5352 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL3989974 — compound record and bioactivity
• PubChem CID 77843966 — chemical identifiers
• DrugBank DB14879 — drug record
• FDA UNII SZ34OMG6E8 — substance identity
• DailyMed: FDA labels for Cefiderocol — current prescribing information (label search)
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.